18 F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma.
| Autor: | Currie GM; Faculty of Science, Charles Sturt University, Wagga Wagga, Australia; gcurrie@csu.edu.au., Trifunovic M; Macquarie Medical Imaging, Macquarie University Hospital, Sydney, Australia; and., Liu J; Macquarie Medical Imaging, Macquarie University Hospital, Sydney, Australia; and., Kim S; Medical Oncology, Macquarie University, Sydney, Australia., Gurney H; Medical Oncology, Macquarie University, Sydney, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of nuclear medicine technology [J Nucl Med Technol] 2022 Sep; Vol. 50 (3), pp. 282-285. Date of Electronic Publication: 2021 Nov 08. |
| DOI: | 10.2967/jnmt.121.262799 |
| Abstrakt: | Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers. (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|